DARE
NASDAQ · Pharmaceuticals
Dare Bioscience Inc
$0.64
+0.02 (+2.40%)
Financial Highlights (FY 2026)
Revenue
1.78M
Net Income
-23,121,562
Gross Margin
71.3%
Profit Margin
-1,300.7%
Rev Growth
-53.1%
D/E Ratio
2.42
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 71.3% | 71.3% | 44.5% | 44.5% |
| Operating Margin | -1,315.5% | -1,184.0% | 16.7% | 17.2% |
| Profit Margin | -1,300.7% | -1,235.6% | 17.9% | 15.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.78M | 3.79M | 6.37M | 6.18M |
| Gross Profit | 1.27M | 2.70M | 2.84M | 2.75M |
| Operating Income | -23,397,588 | -44,918,577 | 1.06M | 1.06M |
| Net Income | -23,121,562 | -44,388,664 | 1.14M | 939.3K |
| Gross Margin | 71.3% | 71.3% | 44.5% | 44.5% |
| Operating Margin | -1,315.5% | -1,184.0% | 16.7% | 17.2% |
| Profit Margin | -1,300.7% | -1,235.6% | 17.9% | 15.2% |
| Rev Growth | -53.1% | -53.1% | +7.5% | -4.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 4.36M | 4.36M | 9.41M | 9.16M |
| Total Equity | 1.80M | 1.80M | 13.13M | 13.27M |
| D/E Ratio | 2.42 | 2.42 | 0.72 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -20,565,574 | -41,675,117 | 1.58M | 1.73M |
| Free Cash Flow | — | — | 772.3K | 654.4K |